Edwards Lifesciences (EW) Enters $325M Accelerated Share Repurchase Agreement

Edwards Lifesciences (NYSE: EW) announced that it has entered into an accelerated share repurchase (ASR) agreement with Morgan Stanley & Co. LLC to repurchase $325 million of Edwards' common stock. This repurchase is part of the Company's previously authorized program to repurchase up to $750 million of the Company's common stock.

Under the terms of the ASR, Edwards has agreed to purchase $325 million of its common stock from Morgan Stanley & Co. LLC with an initial delivery of 3.2 million shares. The final number of shares repurchased and delivered under the ASR will be based on the volume weighted average share price of the Company's common stock over the ASR period, which is expected to be up to ten months, subject to certain adjustments pursuant to the ASR agreement. The Company is funding the ASR with existing available cash.

You May Also Be Interested In

• Morgan Stanley Private Credit Fund Caps Redemptions At 5%
• Genius Group buys back 6M shares, removes 27% of public float
• Aelis Farma discloses share buyback program details